Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.90 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753676 | 0.94 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL1753860 | 0.93 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL4534814 | 0.86 | MCHR1 (0.86) | MCHR1KCNH2HRH3 | |
| SCHEMBL3581020 | 0.85 | NPC1 (0.87) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14970586 | 0.85 | NPC1 (0.87) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2887436 | 0.84 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL2887739 | 0.84 | MCHR1 (0.98) | MCHR1KCNH2HRH3 | |
| SCHEMBL4689454 | 0.83 | KDM4E (0.86) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2895116 | 0.83 | MCHR1 (0.81) | MCHR1KCNH2HRH3 | |
| SCHEMBL2890154 | 0.83 | MCHR1 (1.00) | MCHR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | MCHR1 535/4885KCNH2 1619/4885HRH3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.